Table 1.
Characteristics of the patients treated in WINTHER trial investigated with DDPP.
| Study ID | Age | Sex | Cancer site | Prior lines | PFS months | DNA—list of molecular alterations (Foundation Medicine report)a | Drug_given |
|---|---|---|---|---|---|---|---|
| 203 | 67 | F | GI/NE | 1 | 60.0+ | No mutation | Everolimus |
| 148 | 82 | M | GI/NE | 2 | 11.6 | BCOR N1652fs*34; CDKN1B E126fs*1 | Everolimus |
| 6 | 64 | F | UP | 1 | 8.1 | TSC1 splice site 913 + 1G > T; BRCA1 truncation, intron 11; CDKN2A/B loss; DNMT3A R882H; LRP1B loss | Everolimus |
| 117 | 34 | M | HN | 2 | 1.9 | TSC2 S1431L; TP53 G245S; BCOR K374fs*19; SMARCA4 R1135W | Everolimus |
| 227 | 56 | M | LS | 4 | 1.7 | STK11 F354L; STK11 F354L; TERT promoter —124C > T | Everolimus |
| 90 | 74 | M | HN | 2 | 1.3 | PIK3CA Q546R; EP300 D1154fs*30; NOTCH1 L1746fs*40 | Everolimus |
| 83 | 59 | M | HN | 4 | 8.8 | MTOR L2209V; ETV6 trunc intron 5; CIC S333fs*36; MLL2 G3698 fs*51 | Axitinib |
| 223 | 65 | F | HN | 3 | 7.1 | CCND1 T2861 | Axitinib |
| 259 | 53 | F | HN | 4 | 6.2 | PDGFRA amp | Axitinib |
| 25 | 65 | M | HN | 2 | 5.3 | TP53 I195F; KDM6A L725fs*4; MSH6 K1358fs*2; NFE2L2 R18Q | Axitinib |
| 88 | 56 | M | Lung | 1 | 2.9 | DNMT3A R635P; KRAS G12C; TP53 Y220C; MLL2 T1246M | Axitinib |
| 149 | 54 | F | CRC | 5 | 7.4 | KRAS G12V; ARID1A SPLICE SITE 2733-1G > A | Trametinib |
| 100 | 43 | M | Lung | 2 | 6.6 | BRAF A598_T599insT; IDH1 R132C | Trametinib |
| 118 | 78 | F | Lung | 3 | 3.1 | KRAS G12C; CDKN2A/B loss; TP53 V157F, Y220 fs*27; MUTYH G382D | Trametinib |
| 156 | 71 | F | Lung | 2 | 14.3 | EGFR E746_A750del, T790M; CDKN2A/B loss; CTNNB1 S33F; MYC amplification; SMAD4 P186fs*6; STAG2 splice site 1535-12_1630del108 | Afatinib + cetuximab |
| 235 | 60 | F | Lung | 1 | 11.3 | ERBB2 A775_G776insYVMA | Afatinib |
| 136 | 79 | M | Lung | 3 | 0.4 | ERBB3 amp; MET splice site 3028 + 1G > A; STK11 Q100* ATM L2450fs*11; BRCA1 E23fs*17; CDK4 amp; CDKN2A/B loss; MDM2 amp; APC I1307K; KDM5C truncation; MAP3K1 S1475* | Afatinib |
| 237 | 47 | M | HN | 6 | 19.3 | CCND1 amp; FGFR2 amp; CDKN2A/B loss; FGF19 amp; FGF4 amp; BAP1 trunc exon 3; FGF3 amp; MAGI2 Q1077*; PBRM1 E1155fs*17 | NCT01004224 BGJ398 |
| 247 | 67 | M | Esophagus | 2 | 1.6 | FGFR2 amp; CDKN2A/B loss; TP53 W91*; ASXL1 splice site 472-2A > G | NCT02052778 TAS-120 |
| 228 | 38 | M | CRC | 5 | 0.7 | FGFR1 amp; TP53 C176F; APC E1322*, R213*; SMAD4 loss; SOX9 V163fs*21 | NCT02052778 TAS-120 |
| 183 | 66 | M | CRC | 2 | 61.0+ | RBB3; V104M; MAP2K1; E203K; CDKN2A/B loss; FBXW7 R465C; PIK3CA E39K; PIK3R1 R348*, R639*; PTEN R233*, splice site 801 + 2T > G; TP53 R158H, R273H; APC R1450*, R499*; ARID1A P1115fs*46, Q1306fs*17; ATRX Q2422*; CDH1 D433N; EP300 R2263*; FAM123B R631*; FAT1 A4305V; FLCN H429fs*39; MSH6 L1330fs*12, S279fs*12 |
Pembrolizumab (TMB: 74.8) (MSI: +) |
| 294 | 57 | M | HN | 1 | 1.7 | BRCA2 K3408* |
Nivolumab (TMB: 0) (MSI: −) |
| 270 | 76 | F | CRC | 3 | 0.9 | FLT4 amp; FLT3 amp equivocal; BARD1 C53fs*5; MYC amp; PARK2 loss exons 3–5; TP53 R175H; APC T1556fs*3; BCL2L1 amp; CDK8 amp; ETV6 rearrangement intron 5; FAM123B R497*; GATA6 amp equivocal; KDM6A-Y215*; MUTYH-Y165C; NOTCH1 Q2123* |
Atezolizumab (TMB: 10.4) (MSI: −) |
Foundation Medicinea10; ID 203, PFS 60+ and OS60+ are censored values, updated from the WINTHER trial Supplemental Table 3, Abbreviations: GI gastrointestinal, NE neuroendocrine, HN head and neck, UP unknown primary, LS liposarcoma, TMB tumor mutation burden, MSI microsatellite instability, amp amplification, del deletion, trunc truncation.